Public Market Listing
6990 HKEX
HKEX primary exchange listing
External market data link · No third-party exchange redistribution
Assets (7 total) 7 Total Assets
0 Approved
2 Phase 3 / Filed
5 Phase 1–2 / Early
11 Diseases
Disease: All diseases (7) Non-Small Cell Lung Cancer (4) Breast Cancer (2) Asthma (2) Ovarian Cancer (1) Cervical Cancer (1) Bladder Cancer (1) Endometrial Cancer (1) Nasopharyngeal Carcinoma (1) Chronic Obstructive Pulmonary Disease (1) Solid Tumors (1) Atopic Dermatitis (1)
Stage: All stages (7) Approved / Phase 4 (0) Phase 3 / Filed (2) Phase 2 Phase 1 / Preclinical
Quick filter: All (7) Non-Small Cell Lung Cancer (4) Breast Cancer (2) Asthma (2) Ovarian Cancer (1) Cervical Cancer (1)
Showing 7 of 7 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 TROP2 Antibody–drug conjugate
Non-Small Cell Lung Cancer Breast Cancer Ovarian Cancer Cervical Cancer Bladder Cancer Endometrial Cancer
HR+/HER2- Metastatic Breast Cancer Phase 3 PD-L1 Monoclonal antibody
Non-Small Cell Lung Cancer Breast Cancer Nasopharyngeal Carcinoma
HR+/HER2- Metastatic Breast Cancer Phase 2/3 TSLP Monoclonal antibody
Chronic Obstructive Pulmonary Disease Asthma
Phase 2 EGFR x c-MET Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2 PD-1 + VEGF Multispecific antibody
Phase 1/2 RET Small molecule
Non-Small Cell Lung Cancer
Phase 1 TSLP Multispecific antibody
Upcoming events (56 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (5) November 2026 (1) December 2026 (4) Lunbotinib Phase 1/2 Advanced Solid Tumor Est. primary completion 2026-12-31 ·
NCT05265091 ·
CT.gov ↗ What to watch
2027 (14) March 2027 (1) Est. primary completion 2027-03 ·
NCT05443126 ·
CT.gov ↗ What to watch
April 2027 (1) May 2027 (2) June 2027 (2) SKB571 Phase 2 Non-small Lung Cancer Est. primary completion 2027-06-30 ·
NCT07308106 ·
CT.gov ↗ What to watch
July 2027 (2) August 2027 (2) SKB571 Phase 2 Gastrointestinal Tumors Est. primary completion 2027-08-31 ·
NCT07564466 ·
CT.gov ↗ What to watch
November 2027 (1) Est. primary completion 2027-11-30 ·
NCT05642780 ·
CT.gov ↗ What to watch
December 2027 (3) Tagitanlimab Phase 3 Nasopharyngeal Carcinoma, Recurrent or Metastatic Est. primary completion 2027-12 ·
NCT05294172 ·
CT.gov ↗ What to watch
WIN378 Phase 2 COPD (Chronic Obstructive Pulmonary Disease) Est. primary completion 2027-12-17 ·
NCT07646587 ·
CT.gov ↗ What to watch
2028 (15) January 2028 (4) SKB571 Phase 2 Lung Cancer (Non-Small Cell) Est. primary completion 2028-01-19 ·
NCT07230405 ·
CT.gov ↗ What to watch
February 2028 (1) SKB571 Phase 2 Pancreatic Cancer Est. primary completion 2028-02-28 ·
NCT07814066 ·
CT.gov ↗ What to watch
March 2028 (1) Sacituzumab Tirumotecan Phase 1/2 Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma Est. primary completion 2028-03-31 ·
NCT06483334 ·
CT.gov ↗ What to watch
April 2028 (1) May 2028 (1) Sacituzumab Tirumotecan Phase 1/2 Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer Est. primary completion 2028-05-09 ·
NCT06445972 ·
CT.gov ↗ What to watch
June 2028 (1) Est. primary completion 2028-06-15 ·
NCT06459180 ·
CT.gov ↗ What to watch
August 2028 (2) Est. primary completion 2028-08 ·
NCT07697586 ·
CT.gov ↗ What to watch
September 2028 (1) Est. primary completion 2028-09-30 ·
NCT07668154 ·
CT.gov ↗ What to watch
October 2028 (1) Est. primary completion 2028-10-01 ·
NCT07120503 ·
CT.gov ↗ What to watch
December 2028 (2) SKB571 Phase 2 Non-Small Cell Lung Cancer Est. primary completion 2028-12-31 ·
NCT07622186 ·
CT.gov ↗ What to watch
Tagitanlimab Phase 2 Small Cell Lung Cancer Est. primary completion 2028-12-31 ·
NCT07296809 ·
CT.gov ↗ What to watch
2029 (10) January 2029 (1) February 2029 (1) CR-001 Phase 1/2 Locally Advanced / Metastatic Solid Tumors Est. primary completion 2029-02 ·
NCT07335497 ·
CT.gov ↗ What to watch
April 2029 (2) SKB571 Phase 1/2 Advanced Solid Tumors, Malignant Neoplasm Est. primary completion 2029-04-12 ·
NCT07876128 ·
CT.gov ↗ What to watch
Sacituzumab Tirumotecan Phase 3 Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Est. primary completion 2029-04-27 ·
NCT06824467 ·
CT.gov ↗ What to watch
July 2029 (1) Est. primary completion 2029-07-27 ·
NCT07419295 ·
CT.gov ↗ What to watch
August 2029 (1) September 2029 (1) Sacituzumab Tirumotecan Phase 1/2 Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer Est. primary completion 2029-09-12 ·
NCT06469944 ·
CT.gov ↗ What to watch
October 2029 (1) Sacituzumab Tirumotecan Phase 1/2 Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer Est. primary completion 2029-10-16 ·
NCT06428409 ·
CT.gov ↗ What to watch
November 2029 (1) December 2029 (1) 2030 (2) May 2030 (1) December 2030 (1) 2031 (3) September 2031 (1) October 2031 (1) Est. primary completion 2031-10-29 ·
NCT07216703 ·
CT.gov ↗ What to watch
November 2031 (1) Est. primary completion 2031-11-17 ·
NCT07829783 ·
CT.gov ↗ What to watch
2032 (4) January 2032 (1) February 2032 (1) May 2032 (1) June 2032 (1) 2033 (2) February 2033 (1) March 2033 (1) Sacituzumab Tirumotecan Phase 3 Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms Est. primary completion 2033-03-23 ·
NCT06966700 ·
CT.gov ↗ What to watch
2034 (1) See the full readout calendar ↗
Regulatory and conference events (2) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
8 September 2026 Topline result WIN378 (HBM9378) Positive interim results from the Phase 2 portion of POLARIS-1 (WIN378/HBM9378, asthma); Phase 3 portion started 30 July 2026 Filing accepted Sacituzumab tirumotecan (sac-TMT) NMPA accepts the new indication application for sac-TMT in first-line advanced TNBC China, NMPA · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ·
Source ↗ Financial reports Quarterly & interim (1)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-H1 $131M $84M $632M $20M report ↗
For the first half of 2025, Sichuan Kelun-Biotech reported revenue of $131.14M, R&D spend of $84.38M, and cash and equivalents of $632.1M. Net income/loss was not disclosed; the company recorded a quarterly net burn of $20.04M.
The company is commercializing sac-TMT, tagitanlimab, and cetuximab N01, with total commercial sales of RMB309.8 million in the period, and expects to launch trastuzumab botidotin and file an NDA for A400 in the second half of 2025. Sac-TMT received NMPA marketing authorization for EGFR-mutant NSCLC in March 2025 and an NDA acceptance with priority review for HR+/HER2- breast cancer in May 2025, while partner MSD is running 14 ongoing global Phase 3 studies of the asset. Trastuzumab botidotin's NDA for HER2+ breast cancer was accepted in January 2025. The company is also advancing earlier-stage candidates including SKB410/MK-3120, SKB571/MK-2750, and SKB378/WIN378, alongside collaborations with Ellipses Pharma and Windward Bio.
Annual history (2 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $287M $184M $651M $53M report ↗
View 1 more year Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $269M — $421M $37M report ↗
Latest financial report · 2025-FY
Sichuan Kelun-Biotech reported FY2025 revenue of $286.5M, up 6.5% YoY (prior year $269.03M). R&D spend was $183.73M (approximately RMB1,319.68M in the report). Cash and equivalents stood at $651.26M, with the report also citing approximately RMB4,559.36M in cash and financial assets. The company recorded a loss for the period of RMB381.97M (adjusted annual loss approximately RMB211.28M) and a quarterly net burn of $53.18M.
The company said multiple products had been successfully launched, with four approved products covering eight indications in China and three products with five indications included in the 2025 NRDL. Its pipeline includes more than 30 drug candidates, over 10 in clinical stage, spanning ADC and novel conjugated drug modalities plus non-oncology areas. Key developments included sac-TMT approvals in EGFR-mutant NSCLC, trastuzumab botidotin approval in HER2+ breast cancer, tagitanlimab approval in nasopharyngeal carcinoma, cetuximab N01 approval in mCRC, and an NDA accepted for lunbotinib. Partnerships with MSD, Ellipses Pharma, Windward Bio, and Crescent Biopharma advanced. No numerical guidance was provided.